Is there an optimal irradiation dose for photodynamic therapy: 37 Jcm‐2 or 75 Jcm‐2?

Brian Todd (Lead / Corresponding author), A. Lesar, P. O'Mahoney, E. Eadie, S. H. Ibbotson

Research output: Contribution to journalArticlepeer-review

26 Downloads (Pure)


Topical photodynamic therapy (PDT) is widely used for the treatment of Bowen’s disease (BD) and superficial basal cell carcinoma (BCC). The process involves oxygen‐dependent light activation of the tissue‐localised photosensitiser, protoporphyrin IX, three hours after pro‐drug application to the lesion. Current approved and licensed regimens involve application of either methylaminolevulinate (MAL, Metvix, Galderma, Switzerland) or 5‐aminolaevulinic acid in nanocolloid emulsion (ALA, Ameluz gel, Biofrontera, Germany) and subsequent light activation using narrow spectrum (630‐635 nm) red light (typically light emitting diodes (LEDs)), at an unweighted radiant exposure (“dose”) of 37 Jcm‐2 (1‐3).
Original languageEnglish
Pages (from-to)1287-1288
Number of pages2
JournalBritish Journal of Dermatology
Issue number5
Early online date2 Nov 2019
Publication statusPublished - 13 May 2020

Fingerprint Dive into the research topics of 'Is there an optimal irradiation dose for photodynamic therapy: 37 Jcm<sup>‐2</sup> or 75 Jcm<sup>‐2</sup>?'. Together they form a unique fingerprint.

Cite this